Prashant Shankarrao Adole
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Prashant Shankarrao Adole has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Kolar Vishwanath Vinod
Department of General Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India
6 shared publications Kolar Vishwanath Vinod
Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India
4 shared publications- Ajith Ananthakrishna Pillai
Department of Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India
3 shared publications - Sushmita Bora
Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India
3 shared publications - Ahamed Shaheer Ahmed
Department of Cardiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
2 shared publications - Anusha Cherian
Department of Anaesthesiology and critical care, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
2 shared publications
Latest Publications
- Open Access
- 24 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4) , e82953
Serum Mitsugumin-53 Level as a Diagnostic Marker in Patients With Acute Coronary Syndrome: A Case-Control Study
Background: The high incidence of acute coronary syndrome (ACS) warrants the search for new cardiac biomarkers. Mitsugumin-53 (MG-53) is a myokine involved in cell membrane repair and essential for the function and survival of cardiomyocytes. Therefore, the study assessed the utility of serum MG-53 levels in ACS diagnosis and prognosis. Method: We enrolled 120 ACS patients as cases and 40 healthy controls as per the inclusion and exclusion criteria in this case-control study. The demographics, present and past history, and physical characteristics were recorded. The chemistry analyzer analyzed routine blood investigations. Serum MG-53 and heart-type fatty acid binding protein (H-FABP as a myocardial injury marker) levels were measured using enzyme-linked immunosorbent assay (ELISA) kits. The Statistical Package for the Social Sciences (SPSS) program (version 26.0, IBM Corp., Armonk, NY) was used for statistical analysis, such as independent t-test, chi-squared test, Pearson’s and Spearman’s correlation, receiver operating characteristic (ROC) curve, and univariate and multivariate logistic regression. A p-value <0.05 was considered statistically significant. Results: Patients with ACS as cases had higher serum MG-53 and H-FABP levels than controls (p < 0.001). Serum MG-53 level was significantly positively correlated with serum troponin-I (correlation coefficient (r) = 0.520, p < 0.001), creatine kinase-MB (r = 0.298, p = 0.001), and H-FABP (r = 0.792, p < 0.001). The ROC curve showed that the serum MG-53 level had an area under the curve of 0.846 (95% CI: 0.781-0.911, p < 0.001) and sensitivity and specificity of 70%. Multivariate logistic regression depicted that the serum MG-53 level (OR = 1.113, 95% CI: 1.028-1.297, p < 0.001) was significantly associated with ACS risk after adjusting for age, weight, systolic blood pressure, random blood glucose, and serum total cholesterol levels. Multivariate linear regression showed a significant positive association between serum MG-53 and H-FABP levels in patients with different ACS severity and vessel diseases (p < 0.001). Conclusion: The serum MG-53 level may be considered one of the diagnostic markers in ACS patients. However, further studies need to confirm our findings.
- 24 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4) , e82953
Open AccessSerum Mitsugumin-53 Level as a Diagnostic Marker in Patients With Acute Coronary Syndrome: A Case-Control Study
Background: The high incidence of acute coronary syndrome (ACS) warrants the search for new cardiac biomarkers. Mitsugumin-53 (MG-53) is a myokine involved in cell membrane repair and essential for the function and survival of cardiomyocytes. Therefore, the study assessed the utility of serum MG-53 levels in ACS diagnosis and prognosis. Method: We enrolled 120 ACS patients as cases and 40 healthy controls as per the inclusion and exclusion criteria in this case-control study. The demographics, present and past history, and physical characteristics were recorded. The chemistry analyzer analyzed routine blood investigations. Serum MG-53 and heart-type fatty acid binding protein (H-FABP as a myocardial injury marker) levels were measured using enzyme-linked immunosorbent assay (ELISA) kits. The Statistical Package for the Social Sciences (SPSS) program (version 26.0, IBM Corp., Armonk, NY) was used for statistical analysis, such as independent t-test, chi-squared test, Pearson’s and Spearman’s correlation, receiver operating characteristic (ROC) curve, and univariate and multivariate logistic regression. A p-value <0.05 was considered statistically significant. Results: Patients with ACS as cases had higher serum MG-53 and H-FABP levels than controls (p < 0.001). Serum MG-53 level was significantly positively correlated with serum troponin-I (correlation coefficient (r) = 0.520, p < 0.001), creatine kinase-MB (r = 0.298, p = 0.001), and H-FABP (r = 0.792, p < 0.001). The ROC curve showed that the serum MG-53 level had an area under the curve of 0.846 (95% CI: 0.781-0.911, p < 0.001) and sensitivity and specificity of 70%. Multivariate logistic regression depicted that the serum MG-53 level (OR = 1.113, 95% CI: 1.028-1.297, p < 0.001) was significantly associated with ACS risk after adjusting for age, weight, systolic blood pressure, random blood glucose, and serum total cholesterol levels. Multivariate linear regression showed a significant positive association between serum MG-53 and H-FABP levels in patients with different ACS severity and vessel diseases (p < 0.001). Conclusion: The serum MG-53 level may be considered one of the diagnostic markers in ACS patients. However, further studies need to confirm our findings.
- 12 February 2025
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 46 (1) , 125-133
Diagnostic utility and association of hemodynamic stress biomarkers with biomarkers of myocardial necrosis and plaque instability in type 2 diabetes with acute coronary syndrome: A case–control study
- 12 February 2025
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 46 (1) , 125-133
Diagnostic utility and association of hemodynamic stress biomarkers with biomarkers of myocardial necrosis and plaque instability in type 2 diabetes with acute coronary syndrome: A case–control study
- 25 September 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (3) , 530-537
Elevated Serum Vitamin B12 Levels and Functional Vitamin B12 Deficiency among Patients with Myeloproliferative Neoplasms
Despite elevated serum vitamin B12 levels, functional (i.e., metabolically manifest) vitamin B12 deficiency has been reported in a significant proportion of MPN patients. This study aimed to assess the prevalence of functional vitamin B12 deficiency and elevated serum vitamin B12 levels among Indian MPN patients. This cross-sectional study evaluated serum vitamin B12, homocysteine, methyl malonic acid (MMA) and holotranscobalamin levels among 176 MPN patients. Serum vitamin B12 levels between 150 and 950 pg/mL were considered normal. Functional vitamin B12 deficiency was diagnosed based on combination of elevated serum MMA (> 0.4 nmol/mL) and homocysteine (> 15 µmol/L) levels and low serum holotranscobalamin levels (< 25 pmol/L), irrespective of serum vitamin B12 levels and clinical manifestations of deficiency. Among patients enrolled (n = 176), 108 (61%) had chronic phase CML, 37 (21%) PV, 23 (13%) PMF and 8 (4%) ET. Nearly one-third were newly diagnosed to have MPNs and treatment naïve. Elevated serum vitamin B12 levels (> 950pg/mL) were seen in about a quarter (n = 45) of MPN patients. Half (n = 89) were detected to have functional vitamin B12 deficiency. No association was found between functional vitamin B12 deficiency and serum vitamin B12 levels and functional deficiency prevalence did not differ significantly between different types of MPNs and between newly diagnosed (treatment-naïve) and already treated MPNs. About a quarter of MPN patients had elevated serum B12 levels and half had functional vitamin B12 deficiency. Functional deficiency was diagnosed independent of serum vitamin B12 levels. Hence, evaluation for functional deficiency should be carried out irrespective of serum vitamin B12 levels. Future studies should evaluate potential benefit of vitamin B12 replacement in MPN patients with functional vitamin B12 deficiency.
- 25 September 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (3) , 530-537
Elevated Serum Vitamin B12 Levels and Functional Vitamin B12 Deficiency among Patients with Myeloproliferative Neoplasms
Despite elevated serum vitamin B12 levels, functional (i.e., metabolically manifest) vitamin B12 deficiency has been reported in a significant proportion of MPN patients. This study aimed to assess the prevalence of functional vitamin B12 deficiency and elevated serum vitamin B12 levels among Indian MPN patients. This cross-sectional study evaluated serum vitamin B12, homocysteine, methyl malonic acid (MMA) and holotranscobalamin levels among 176 MPN patients. Serum vitamin B12 levels between 150 and 950 pg/mL were considered normal. Functional vitamin B12 deficiency was diagnosed based on combination of elevated serum MMA (> 0.4 nmol/mL) and homocysteine (> 15 µmol/L) levels and low serum holotranscobalamin levels (< 25 pmol/L), irrespective of serum vitamin B12 levels and clinical manifestations of deficiency. Among patients enrolled (n = 176), 108 (61%) had chronic phase CML, 37 (21%) PV, 23 (13%) PMF and 8 (4%) ET. Nearly one-third were newly diagnosed to have MPNs and treatment naïve. Elevated serum vitamin B12 levels (> 950pg/mL) were seen in about a quarter (n = 45) of MPN patients. Half (n = 89) were detected to have functional vitamin B12 deficiency. No association was found between functional vitamin B12 deficiency and serum vitamin B12 levels and functional deficiency prevalence did not differ significantly between different types of MPNs and between newly diagnosed (treatment-naïve) and already treated MPNs. About a quarter of MPN patients had elevated serum B12 levels and half had functional vitamin B12 deficiency. Functional deficiency was diagnosed independent of serum vitamin B12 levels. Hence, evaluation for functional deficiency should be carried out irrespective of serum vitamin B12 levels. Future studies should evaluate potential benefit of vitamin B12 replacement in MPN patients with functional vitamin B12 deficiency.
- Open Access
- 31 August 2024
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 28 (9) , 832-836
Prevalence of Diastolic Dysfunction in Critically Ill Patients Admitted to Intensive Care Unit from a Tertiary Care Hospital: A Prospective Observational Study
Aim: Critically ill individuals may have left ventricular diastolic dysfunction (LVDD) which can prolong their intensive care unit (ICU) stay. The purpose of this study was to determine the prevalence of LVDD in critically ill adult patients requiring mechanical ventilation in ICU, the effect of LVDD on 28-day survival, and weaning from mechanical ventilation. Methodology: A total of 227 adults who had been on mechanical ventilation for more than 48 hours in an ICU were recruited for this study. The study's parameters were recorded on the third day of mechanical ventilation using a low-frequency phased array probe. A simplified definition of LVDD in critically ill adults was utilized to determine the presence or absence of LVDD. Weaning failure and 28-day mortality were noted. Results: The prevalence of LVDD in adults requiring mechanical ventilation in the ICU was found to be 35.4% (n n = 79). Patients with LVDD had the odds of having a 28-day mortality increase by 7.48 (95% CI: 3.24-17.26, p < 0.0001). Patients with LVDD had the odds of having weaning failure increase by 5.37 (95% CI: 2.17-13.26, p = 0.0003). Conclusion: Measures should be taken to detect critically ill adults with LVDD with systolic dysfunction or heart failure with preserved ejection fraction early so that their fluid balance, myocardial contractility, and afterload can be optimized to minimize their morbidity and mortality.
- 31 August 2024
- Published by Jaypee Brothers Medical Publishing in Indian Journal of Critical Care Medicine
- Vol. 28 (9) , 832-836
Open AccessPrevalence of Diastolic Dysfunction in Critically Ill Patients Admitted to Intensive Care Unit from a Tertiary Care Hospital: A Prospective Observational Study
Aim: Critically ill individuals may have left ventricular diastolic dysfunction (LVDD) which can prolong their intensive care unit (ICU) stay. The purpose of this study was to determine the prevalence of LVDD in critically ill adult patients requiring mechanical ventilation in ICU, the effect of LVDD on 28-day survival, and weaning from mechanical ventilation. Methodology: A total of 227 adults who had been on mechanical ventilation for more than 48 hours in an ICU were recruited for this study. The study's parameters were recorded on the third day of mechanical ventilation using a low-frequency phased array probe. A simplified definition of LVDD in critically ill adults was utilized to determine the presence or absence of LVDD. Weaning failure and 28-day mortality were noted. Results: The prevalence of LVDD in adults requiring mechanical ventilation in the ICU was found to be 35.4% (n n = 79). Patients with LVDD had the odds of having a 28-day mortality increase by 7.48 (95% CI: 3.24-17.26, p < 0.0001). Patients with LVDD had the odds of having weaning failure increase by 5.37 (95% CI: 2.17-13.26, p = 0.0003). Conclusion: Measures should be taken to detect critically ill adults with LVDD with systolic dysfunction or heart failure with preserved ejection fraction early so that their fluid balance, myocardial contractility, and afterload can be optimized to minimize their morbidity and mortality.
- 5 July 2024
- Published by Wiley in Biomedical Chromatography
- Vol. 38 (9) , e5952
GC–MS validation and analysis of targeted plasma metabolites related to carbonyl stress in type 2 diabetes mellitus patients with and without acute coronary syndrome
Methylglyoxal (MG) is responsible for advanced glycation end‐product formation, the mechanisms leading to diabetes pathogenesis and complications like acute coronary syndrome (ACS). Sugar metabolites, amino acids and fatty acids are possible substrates for MG. The study aimed to measure plasma MG substrate levels using a validated gas chromatography–mass spectrometry (GC–MS) method and explore their association with ACS risk in type 2 diabetes mellitus (T2DM). The study included 150 T2DM patients with ACS as cases and 150 T2DM without ACS as controls for the analysis of glucose, fructose, ribulose, sorbitol, glycerol, pyruvate, lactate, glycine, serine, threonine, C16:0, C16:1, C18:0, C18:1, C18:2, C18:3, C20:0 and C22:6 by GC–MS. Validated GC–MS methods were accurate, precise and sensitive. Cases significantly differed in plasma MG and metabolite levels except for lactate, C16:0, C18:0, C18:2, and C18:3 levels compared with controls. On multivariable logistic regression, plasma C20:0, C18:1, glycine and glycerol levels had increased odds of ACS risk. On multivariate receiver operating characteristic analysis, a model containing plasma C20:0, C16:1, C18:1, C18:2, serine, glycerol, lactate and threonine levels had the highest area under the curve value (0.932) for ACS diagnosis. In conclusion, plasma C20:0, C16:1, C18:1, glycine, glycerol and sorbitol levels were associated with ACS risk in T2DM.
- 5 July 2024
- Published by Wiley in Biomedical Chromatography
- Vol. 38 (9) , e5952
GC–MS validation and analysis of targeted plasma metabolites related to carbonyl stress in type 2 diabetes mellitus patients with and without acute coronary syndrome
Methylglyoxal (MG) is responsible for advanced glycation end‐product formation, the mechanisms leading to diabetes pathogenesis and complications like acute coronary syndrome (ACS). Sugar metabolites, amino acids and fatty acids are possible substrates for MG. The study aimed to measure plasma MG substrate levels using a validated gas chromatography–mass spectrometry (GC–MS) method and explore their association with ACS risk in type 2 diabetes mellitus (T2DM). The study included 150 T2DM patients with ACS as cases and 150 T2DM without ACS as controls for the analysis of glucose, fructose, ribulose, sorbitol, glycerol, pyruvate, lactate, glycine, serine, threonine, C16:0, C16:1, C18:0, C18:1, C18:2, C18:3, C20:0 and C22:6 by GC–MS. Validated GC–MS methods were accurate, precise and sensitive. Cases significantly differed in plasma MG and metabolite levels except for lactate, C16:0, C18:0, C18:2, and C18:3 levels compared with controls. On multivariable logistic regression, plasma C20:0, C18:1, glycine and glycerol levels had increased odds of ACS risk. On multivariate receiver operating characteristic analysis, a model containing plasma C20:0, C16:1, C18:1, C18:2, serine, glycerol, lactate and threonine levels had the highest area under the curve value (0.932) for ACS diagnosis. In conclusion, plasma C20:0, C16:1, C18:1, glycine, glycerol and sorbitol levels were associated with ACS risk in T2DM.
- 5 July 2024
- Published by Springer Nature in Biochemical Genetics
- Vol. 63 (4) , 3399-3413
The Relationship Between GAPDH Gene Polymorphism and Risk of Acute Coronary Syndrome in South Indians with Type 2 Diabetes Mellitus
As glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is one of the regulators of carbonyl stress, a pathogenic mechanism for diabetic complications like acute coronary syndrome (ACS), the study aimed to investigate the relationship between GAPDH gene polymorphism, GAPDH activity in red blood cell (RBC), methylglyoxal (MG) levels in plasma and ACS risk in South Indians with type 2 diabetes mellitus (T2DM). This study comprised 150 T2DM with ACS as cases and 150 T2DM without ACS as controls. The GAPDH rs1136666, rs1060620 and rs1060619 gene polymorphisms were identified by TaqMan probe assays. The RBC GAPDH activity and plasma MG levels were estimated. Cases had significantly higher plasma MG levels and lower RBC GAPDH activity than controls (P < 0.001). The distribution of rs1060620 or rs1060619 alleles and genotypes significantly differed between groups. The rs1060620 AG (OR 0.55; 95% CI 0.33–0.92; P = 0.022) or rs1060619 CT (OR 0.51; 95% CI 0.31–0.83; P = 0.007) genotype was associated with reduced ACS risk, confirmed in the over-dominant genetic model. Haplotype analyses revealed that the GAT and CGC haplotypes were associated with increased (OR 28.37; 95% CI 3.82–210.49; P = 8.51 × 10–7) and decreased (OR 0.45; 95% CI 0.24–0.86; P = 0.014) ACS risk in T2DM patients, respectively. Lower GAPDH activity was observed in the TT and CT genotypes compared to the CC genotype of rs1060619 (P < 0.001). This work established that the GAPDH rs1060620 or rs1060619 gene polymorphisms are associated with ACS risk in South Indians with T2DM.
- 5 July 2024
- Published by Springer Nature in Biochemical Genetics
- Vol. 63 (4) , 3399-3413
The Relationship Between GAPDH Gene Polymorphism and Risk of Acute Coronary Syndrome in South Indians with Type 2 Diabetes Mellitus
As glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is one of the regulators of carbonyl stress, a pathogenic mechanism for diabetic complications like acute coronary syndrome (ACS), the study aimed to investigate the relationship between GAPDH gene polymorphism, GAPDH activity in red blood cell (RBC), methylglyoxal (MG) levels in plasma and ACS risk in South Indians with type 2 diabetes mellitus (T2DM). This study comprised 150 T2DM with ACS as cases and 150 T2DM without ACS as controls. The GAPDH rs1136666, rs1060620 and rs1060619 gene polymorphisms were identified by TaqMan probe assays. The RBC GAPDH activity and plasma MG levels were estimated. Cases had significantly higher plasma MG levels and lower RBC GAPDH activity than controls (P < 0.001). The distribution of rs1060620 or rs1060619 alleles and genotypes significantly differed between groups. The rs1060620 AG (OR 0.55; 95% CI 0.33–0.92; P = 0.022) or rs1060619 CT (OR 0.51; 95% CI 0.31–0.83; P = 0.007) genotype was associated with reduced ACS risk, confirmed in the over-dominant genetic model. Haplotype analyses revealed that the GAT and CGC haplotypes were associated with increased (OR 28.37; 95% CI 3.82–210.49; P = 8.51 × 10–7) and decreased (OR 0.45; 95% CI 0.24–0.86; P = 0.014) ACS risk in T2DM patients, respectively. Lower GAPDH activity was observed in the TT and CT genotypes compared to the CC genotype of rs1060619 (P < 0.001). This work established that the GAPDH rs1060620 or rs1060619 gene polymorphisms are associated with ACS risk in South Indians with T2DM.
- 29 June 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (2) , 245-251
Daily Versus Alternate Day Oral Iron Replacement for Women with Iron Deficiency Anaemia: A Randomized Controlled Trial
The optimal way of oral iron replacement for iron deficiency anaemia(IDA) is still unknown and few recent studies have reported better fractional absorption and tolerability of intermittently administered iron. This randomised, active comparator controlled, open-label trial evaluated efficacy and tolerability of 120 mg elemental iron (2 × 200 mg ferrous sulphate tablets) administered as a single dose on alternate days (alternate-day arm, ADA) vis-à-vis 60 mg elemental iron (single FeSO4 tablet) administered daily (daily arm, DA), among women (age ≥ 18 years) having IDA, with haemoglobin (Hb) concentration between 6 and 10 g/dL and serum ferritin < 30 µg/L. Primary outcome was the Hb change on Day-28. Secondary outcomes included Hb change on Day-56, change in serum hepcidin levels from baseline to Day-14, adverse effects (AEs) and compliance to treatment. Sixty-eight participants (34 each in DA and ADA) were enrolled in the trial. Hb change at Day-28 was significantly higher in the ADA compared to DA (mean change: +2.2 ± 1.3 vs. +1.3 ± 1.1 g/dL, p = 0.003). Though Hb increment at Day-56 was also higher in ADA, it was not statistically significant. There was no significant difference in changes in serum hepcidin from baseline to Day-14 between the arms. Significantly higher proportion in the DA had AEs compared to ADA (45% vs. 9%, p < 0.005). However, treatment compliance was not significantly different between the arms. Alternate-day oral iron replacement led to significantly higher haemoglobin increment in the short run and caused significantly lesser AEs compared to daily replacement. Larger multicentric RCTs with longer duration of intervention should evaluate alternate-day replacement vis-à-vis daily therapy in future. This randomised controlled trial has been registered in Clinical Trial Registry-India (CTRI Reg. No.: CTRI/2021/12/038370, dated 2nd December 2021).
- 29 June 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (2) , 245-251
Daily Versus Alternate Day Oral Iron Replacement for Women with Iron Deficiency Anaemia: A Randomized Controlled Trial
The optimal way of oral iron replacement for iron deficiency anaemia(IDA) is still unknown and few recent studies have reported better fractional absorption and tolerability of intermittently administered iron. This randomised, active comparator controlled, open-label trial evaluated efficacy and tolerability of 120 mg elemental iron (2 × 200 mg ferrous sulphate tablets) administered as a single dose on alternate days (alternate-day arm, ADA) vis-à-vis 60 mg elemental iron (single FeSO4 tablet) administered daily (daily arm, DA), among women (age ≥ 18 years) having IDA, with haemoglobin (Hb) concentration between 6 and 10 g/dL and serum ferritin < 30 µg/L. Primary outcome was the Hb change on Day-28. Secondary outcomes included Hb change on Day-56, change in serum hepcidin levels from baseline to Day-14, adverse effects (AEs) and compliance to treatment. Sixty-eight participants (34 each in DA and ADA) were enrolled in the trial. Hb change at Day-28 was significantly higher in the ADA compared to DA (mean change: +2.2 ± 1.3 vs. +1.3 ± 1.1 g/dL, p = 0.003). Though Hb increment at Day-56 was also higher in ADA, it was not statistically significant. There was no significant difference in changes in serum hepcidin from baseline to Day-14 between the arms. Significantly higher proportion in the DA had AEs compared to ADA (45% vs. 9%, p < 0.005). However, treatment compliance was not significantly different between the arms. Alternate-day oral iron replacement led to significantly higher haemoglobin increment in the short run and caused significantly lesser AEs compared to daily replacement. Larger multicentric RCTs with longer duration of intervention should evaluate alternate-day replacement vis-à-vis daily therapy in future. This randomised controlled trial has been registered in Clinical Trial Registry-India (CTRI Reg. No.: CTRI/2021/12/038370, dated 2nd December 2021).
- 28 March 2024
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 28 (3) , 114-122
Association of Tenascin-C Gene Polymorphisms with Risk of Acute Coronary Syndrome in South Indian Population: A Case−Control Genetic Association Study
Background: The extracellular matrix (ECM) glycoprotein changes are associated with the pathogenesis and complications of atherosclerosis, leading to acute coronary syndrome (ACS). Tenascin-C (TNC), an ECM protein, has been implemented in the pathogenesis, diagnosis, and prognosis of patients with cardiovascular disease. Aim: The study aimed to compare the genetic variants of the TNC gene (rs13321, rs2104772, and rs12347433) between South Indians with ACS and healthy participants. Materials and Methods: This case−control study recruited 150 ACS patients as cases and 150 healthy participants as controls. TNC genotyping was performed using TaqMan 5′-exonuclease allele discrimination assay. Serum TNC levels were measured by enzyme-linked immunosorbent assay. Results: Serum TNC levels were significantly higher in cases compared with controls. No significant difference was observed in allele and genotype frequencies of rs13321, rs2104772, and rs12347433 between cases and controls, which was confirmed by dominant, recessive, codominant, and homozygotic genetic models. The patients with heterozygous genotypes of rs13321, rs2104772, and rs12347433 had significantly lower serum TNC levels than patients with respective homozygous genotypes. Haplotype analyses revealed that the C-T-A haplotype in the block of rs13321-rs12347433-rs2104772 was associated with lower ACS risk (OR = 0.33, 95% CI: 0.15 − 0.75; p = 0.005). Also, the C-T-T and G-T-A haplotypes of the TNC gene were associated with higher and lower serum TNC levels, respectively. Conclusion: Our study demonstrated no genetic association between single nucleotide polymorphisms of the TNC gene and ACS risk; however, the C-T-A haplotype of the TNC gene might be associated with reduced ACS risk in South Indians.
- 28 March 2024
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 28 (3) , 114-122
Association of Tenascin-C Gene Polymorphisms with Risk of Acute Coronary Syndrome in South Indian Population: A Case−Control Genetic Association Study
Background: The extracellular matrix (ECM) glycoprotein changes are associated with the pathogenesis and complications of atherosclerosis, leading to acute coronary syndrome (ACS). Tenascin-C (TNC), an ECM protein, has been implemented in the pathogenesis, diagnosis, and prognosis of patients with cardiovascular disease. Aim: The study aimed to compare the genetic variants of the TNC gene (rs13321, rs2104772, and rs12347433) between South Indians with ACS and healthy participants. Materials and Methods: This case−control study recruited 150 ACS patients as cases and 150 healthy participants as controls. TNC genotyping was performed using TaqMan 5′-exonuclease allele discrimination assay. Serum TNC levels were measured by enzyme-linked immunosorbent assay. Results: Serum TNC levels were significantly higher in cases compared with controls. No significant difference was observed in allele and genotype frequencies of rs13321, rs2104772, and rs12347433 between cases and controls, which was confirmed by dominant, recessive, codominant, and homozygotic genetic models. The patients with heterozygous genotypes of rs13321, rs2104772, and rs12347433 had significantly lower serum TNC levels than patients with respective homozygous genotypes. Haplotype analyses revealed that the C-T-A haplotype in the block of rs13321-rs12347433-rs2104772 was associated with lower ACS risk (OR = 0.33, 95% CI: 0.15 − 0.75; p = 0.005). Also, the C-T-T and G-T-A haplotypes of the TNC gene were associated with higher and lower serum TNC levels, respectively. Conclusion: Our study demonstrated no genetic association between single nucleotide polymorphisms of the TNC gene and ACS risk; however, the C-T-A haplotype of the TNC gene might be associated with reduced ACS risk in South Indians.
- 5 March 2024
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 40 (3) , 496-504
Exploring the Diagnostic Utility of Serum Cofilin-1 and 2 Levels in Patients with Acute Coronary Syndrome: A Case–Control Pilot Study
Acute coronary syndrome (ACS) is caused by decreased blood flow to the heart muscle after plaque rupture and thrombus formation, leading to ischemia and infarction. Cofilins are the proteins involved in actin dynamics by severing and dissociating actin filaments. Abnormal cofilins are associated with myopathies, idiopathic dilated cardiomyopathies, etc. As ACS prevalence is increasing and there is a need to find specific biomarkers for ACS diagnosis, the study aimed to assess the diagnostic utility of serum cofilin-1 (CFL-1) and 2 (CFL-2) levels in ACS patients. Forty-five ACS patients as cases and 45 healthy participants as controls were recruited in a case-control pilot study. Collected blood was used to measure serum CFL-1, CFL-2 and heart-type fatty acid-binding protein (H-FABP, a marker of myocardial infarction) levels. Serum CFL-2 levels were significantly lower in cases compared to controls (2.93 [1.95-3.32] vs. 4.35 [3.4-6.61], p < 0.05). No significant difference was observed in serum CFL-1 levels between groups. Serum CFL-2 levels were negatively associated with creatine kinase-total, creatine kinase-MB, creatine kinase-MB relative index, troponin-T, and H-FABP (p < 0.05). Binary logistic regression showed lower CFL-2 levels were associated with a 2.45-fold increased ACS risk. ROC analysis showed no advantage of serum CFL-2 levels over serum H-FABP levels for ACS diagnosis (AUC: 0.120 Vs 0.710, p > 0.05). In conclusion, serum CFL-1 and 2 levels may not have greater significance in ACS diagnosis than traditional cardiac biomarkers. However, further cohort studies with a larger sample size must confirm the study's findings.
- 5 March 2024
- Published by Springer Nature in Indian Journal of Clinical Biochemistry
- Vol. 40 (3) , 496-504
Exploring the Diagnostic Utility of Serum Cofilin-1 and 2 Levels in Patients with Acute Coronary Syndrome: A Case–Control Pilot Study
Acute coronary syndrome (ACS) is caused by decreased blood flow to the heart muscle after plaque rupture and thrombus formation, leading to ischemia and infarction. Cofilins are the proteins involved in actin dynamics by severing and dissociating actin filaments. Abnormal cofilins are associated with myopathies, idiopathic dilated cardiomyopathies, etc. As ACS prevalence is increasing and there is a need to find specific biomarkers for ACS diagnosis, the study aimed to assess the diagnostic utility of serum cofilin-1 (CFL-1) and 2 (CFL-2) levels in ACS patients. Forty-five ACS patients as cases and 45 healthy participants as controls were recruited in a case-control pilot study. Collected blood was used to measure serum CFL-1, CFL-2 and heart-type fatty acid-binding protein (H-FABP, a marker of myocardial infarction) levels. Serum CFL-2 levels were significantly lower in cases compared to controls (2.93 [1.95-3.32] vs. 4.35 [3.4-6.61], p < 0.05). No significant difference was observed in serum CFL-1 levels between groups. Serum CFL-2 levels were negatively associated with creatine kinase-total, creatine kinase-MB, creatine kinase-MB relative index, troponin-T, and H-FABP (p < 0.05). Binary logistic regression showed lower CFL-2 levels were associated with a 2.45-fold increased ACS risk. ROC analysis showed no advantage of serum CFL-2 levels over serum H-FABP levels for ACS diagnosis (AUC: 0.120 Vs 0.710, p > 0.05). In conclusion, serum CFL-1 and 2 levels may not have greater significance in ACS diagnosis than traditional cardiac biomarkers. However, further cohort studies with a larger sample size must confirm the study's findings.